Munich, Germany

Hartmut Engelmann



Average Co-Inventor Count = 4.7

ph-index = 8

Forward Citations = 216(Granted Patents)


Company Filing History:


Years Active: 1993-2012

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents

Title: **Hartmut Engelmann: A Leader in Tumor Necrosis Factor Research**

Introduction

Hartmut Engelmann, an accomplished inventor based in Munich, Germany, holds an impressive portfolio of 13 patents. His work primarily focuses on the field of tumor necrosis factor (TNF) and its related proteins, showcasing his significant contributions to medical research and biotechnology.

Latest Patents

Among his notable patents is the isolated cDNA encoding tumor necrosis factor binding protein II, pertaining to its purification, and the various vectors, hosts, and processes associated with this cDNA. This innovative DNA molecule encodes a vital fragment of TNF Binding Protein II that is essential for developing antibodies capable of targeting this polypeptide. Engelmann's discoveries provide a basis for creating replicable expression vehicles and prokaryotic or eukaryotic expression host cells, which can be instrumental in producing polypeptides associated with such DNA molecules. Another significant patent involves methods for determining the level of human TBP-II using anti-TBP-II antibodies. This patent includes antibodies for tumor necrosis factor receptors and outlines methods for producing them, as well as their application in immunoassays and the purification of TBP-II through affinity chromatography. A diagnostic assay for endogenous antibodies to TBP-II is also covered in this innovative approach.

Career Highlights

Throughout his career, Engelmann has made substantial strides in research and development, particularly at Yeda Research and Development Co. Ltd., where he contributes his expertise to push the boundaries of TNF research. His dedication to advancing scientific knowledge has resulted in numerous patents that enhance the understanding and treatment of various diseases linked to TNF.

Collaborations

Engelmann’s work is often collaborative, involving esteemed colleagues such as David Wallach and Menachem Rubinstein. These partnerships underscore the importance of teamwork in scientific research and highlight the collaborative spirit that drives innovation in the biotechnology sector.

Conclusion

Hartmut Engelmann remains a key figure in the field of tumor necrosis factor research, with his inventions paving the way for advancements in medical treatments and diagnostics. His extensive patent portfolio and collaborative efforts demonstrate a commitment to enhancing human health through innovative scientific discoveries.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…